Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

NCT02097459 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Anastrozole
DRUG: Tamoxifen
DRUG: Toremifene

Sponsor

Peking Union Medical College Hospital